Biogen Appoints Sanjay Jariwala as SVP, Worldwide Medical
September 12 2017 - 7:30AM
Business Wire
Biogen (NASDAQ: BIIB) announced today the appointment of Dr.
Sanjay Jariwala as Senior Vice President, Worldwide Medical.
Dr. Jariwala will be responsible for leading and driving
Biogen’s Worldwide Medical strategy working closely with the
company’s Global Therapeutic Operations and Research and
Development leadership teams. He will be based in Cambridge, Mass.,
and report directly to Chief Medical Officer Alfred Sandrock, Jr.,
M.D., Ph.D.
Dr. Jariwala joins Biogen from AstraZeneca Pharmaceuticals,
where he held the roles of Vice President, Head of Strategy and
Vice President of Infection, Neuroscience, Autoimmunity and
Anti-thrombotics, Global Medical Affairs. During his time at
AstraZeneca, he led the transformation of the Worldwide Medical
Affairs Council, developed a strategic medical planning process to
align commercial operations and R&D priorities, and created and
established a new medical operating model for both medical strategy
and execution at the global, regional, and local levels.
“Sanjay’s depth of experience and track record of strategic
integration of global therapeutic operations, clinical development,
commercial, and state of the art medical leadership across large
organizations is impressive,” said Dr. Sandrock. “He will be an
important addition to the Biogen team as we continue to execute on
our mission to transform the lives of patients with complex
neurological and neurodegenerative disorders.”
Prior to AstraZeneca, Dr. Jariwala was Senior Vice President,
Global Head of Business Development and a member of the Executive
Committee at Vifor Pharma in Zurich, and prior to that at Aspreva
Pharmaceuticals in Vancouver. His industry experience also includes
several senior Medical Affairs and Clinical Development leadership
roles at GlaxoSmithKline in the cardiovascular, metabolic, and
urology therapy areas. Before moving to industry, he was a
practicing physician for the National Health Service in the
U.K.
“I am delighted to join Biogen to lead its Medical group at this
important time,” said Dr. Jariwala. “I believe that Biogen has the
leadership, the credibility, and the courage required to create a
state-of-the-art worldwide medical function that will lead from the
front.”
Dr. Jariwala holds a Master’s degree in Medical Sciences from
Christ’s College, University of Cambridge, England. He received his
medical degree and completed his medical training at the University
of Cambridge, while based at Addenbrookes Hospital.
About BiogenThrough cutting-edge science and medicine,
Biogen discovers, develops and delivers worldwide innovative
therapies for people living with serious neurological and
neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in
biotechnology, and today the company has the leading portfolio of
medicines to treat multiple sclerosis; has introduced the first and
only approved treatment for spinal muscular atrophy; and is at the
forefront of neurology research for conditions including
Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral
sclerosis. Biogen also manufactures and commercializes biosimilars
of advanced biologics. For more information, please visit
www.biogen.com. Follow us on social media – Twitter, LinkedIn,
Facebook, YouTube.
Biogen Safe HarborThis press release contains
forward-looking statements, made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995,
including statements relating to Biogen’s business activities, our
worldwide medical function and strategy, and the expected benefits
from Dr. Jariwala’s appointment as our Senior Vice President,
Worldwide. These forward-looking statements may be accompanied by
words such as “aim,” “anticipate,” “believe,” “could,” “estimate,”
“except,” “forecast,” “intend,” “may,” “plan,” “potential,”
“possible,” “will” and other words and terms of similar meaning.
You should not place undue reliance on these statements.
These statements involve risks and uncertainties that could
cause actual results to differ materially from those reflected in
such statements, including, without limitation: risks relating to
management and key personnel changes; failure to compete
effectively; difficulties in obtaining and maintaining adequate
coverage, pricing and reimbursement for our products; potential
future healthcare reforms; the occurrence of adverse safety events;
failure to protect and enforce our data, intellectual property and
other proprietary rights and uncertainties relating to intellectual
property claims and challenges; uncertainty of success in
developing, licensing or acquiring other product candidates or
additional indications for existing products; delay in approval of
our drug candidates; product liability claims; and third party
collaboration risks. The foregoing sets forth many, but not all, of
the factors that could cause actual results to differ from our
expectations in any forward-looking statement. Investors should
consider this cautionary statement, as well as the risk factors
identified in Biogen’s most recent annual or quarterly report and
in other reports Biogen has filed with the U.S. Securities and
Exchange Commission. These statements are based on our current
beliefs and expectations and speak only as of the date of this
press release. We do not undertake any obligation to publicly
update any forward-looking statements, whether as a result of new
information, future developments or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170912005389/en/
BiogenMEDIA CONTACT:Matt Fearer, +1
617-679-4462public.affairs@biogen.comorINVESTOR CONTACT:Mike Henke,
+1 781-464-2442IR@biogen.com
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Apr 2024 to May 2024
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From May 2023 to May 2024